Drugs / RD-IIT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06786299 | Feb 2025 → Oct 2026 expected | acute myeloid leukemia | First Affiliated Hospital of Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD-IIT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06786299 ↗ |
| Modality | Cell therapy | “Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy” NCT06786299 ↗ |
| Route | Intravenous | “single one-time intravenous infusion of RD-IIT-001” NCT06786299 ↗ |
| Target | CD84 | “Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy” NCT06786299 ↗ |